

# **The management of CML: current treatment paradigms and future perspectives**

**An educational day for European fellows on behalf of  
EUTOS for CML**

**CEINGE – Biotecnologie Mediche  
Faculty of Medicine, University Federico II, Naples**

**18 – 19 May 2009**

## **Introduction and objectives**

### **F Pane**


EUTOS for CML



*European Treatment and Outcome Study*

**161 centers  
in 32  
countries**

- 100 national leukemia study groups
- 103 interdisciplinary partner groups
- 1000 physicians and scientists
- Caring for some ten thousand patients



# History of Chronic Myeloid Leukemia

## *From the bench to the bedside*


- 1845 First description of Chronic Myeloid Leukemia
- 1960 Discovery of the Philadelphia chromosome
- 1973 Recognition of translocation t(9;22)
- 1984 Definition of breakpoint cluster region (*bcr*) on chromosome 22q
- 1985 Discovery of the P210<sup>BCR/ABL</sup> protein with high tyrosine kinase activity
- 1987 Demonstration of *BCR/ABL* fusion gene in some cases of Ph-negative CML
- 1990 Mouse model of CML produced with retroviral vector containing human *BCR/ABL* gene
- 1998 The first CML patient has been treated with Glivec<sup>®</sup> (Imatinib, formerly STI571)

EUTOS for CML



European Treatment and Outcome Study

# 140 Years of CML Therapy



EUTOS for CML



European Treatment and Outcome Study

# Meeting objectives

During the course of this meeting we aim to:

- Create an exciting learning environment for European hematologists like yourselves, who may not usually have an opportunity to attend major congresses
- Provide you with up-to-date information in the field of CML therapy
- Create opportunities for you to discuss CML therapy with leading hematologists

EUTOS for CML



*European Treatment and Outcome Study*

# About the meeting

- The meeting will be hosted by myself and a panel leading hematologists
- It will be composed of three educational sessions as follows:
  - Session 1: First-line treatment approaches in CML
  - Session 2: Prognostic factors for treatment response in CML
  - Session 3: Second-line treatment approaches in CML
- Similar events will be planned by ELN and EUTOS in future

EUTOS for CML



*European Treatment and Outcome Study*

# Agenda: Day 1

## Session 1: First-line treatment approaches in CML

- 14.00 Introduction and objectives – *F Pane*
- 14.10 The biology of CML – *G Saglio*
- 14.35 First line treatment of CML with imatinib: the IRIS trial and the GIMEMA trials – *M Baccarani*
- 15.05 Unsatisfactory treatment response: more imatinib or 2nd generation TK inhibitors? – *G Rosti*
- 15.35 **REFRESHMENT BREAK**
- 15.55 Living with CML: practical management and long-term treatment effects – *L Luciano*
- 16.15 CML in elderly patients and children – *G Rosti*
- 16.35 Q&A session – *Panel*
- 16.50 Clinical case presentations 1 & 2 – *A Hochhaus and S Saussele*
- 17.10 Session wrap-up – *M Baccarani*
- 17.15 **SESSION CLOSE**

EUTOS for CML



European Treatment and Outcome Study

# Agenda: Day 2

## Session 2: Prognostic factors for treatment response in CML

- 08.30 **Welcome back – *G Martinelli***
- 08.35 **BCR-ABL quantitation and mutation detection: methods of disease monitoring and the challenge of standardization – *A Hochhaus***
- 09.00 **The role of stem cell transplantation in CML treatment, and accelerated and blast phase management – *S Saussele***
- 09.15 **Metabolism of imatinib and other TK inhibitors: importance of blood level testing – *F X Mahon***
- 09.40 **Cellular and molecular mechanisms of imatinib resistance – *A Hochhaus***
- 10.00 **Q&A session – *Panel***
- 10.15 **Clinical case presentations 3 & 4 – *G Martinelli and G Rosti***
- 10.35 **REFRESHMENT BREAK**

EUTOS for CML



European Treatment and Outcome Study

# Agenda: Day 2

## Session 3: Second-line treatment approaches in CML

- 10.50 **New generation TK inhibitors in patients with treatment resistance** – *G Martinelli*
- 11.10 **New generation TK inhibitors in front-line therapy** – *F Pane*
- 11.30 **Minimal residual disease in responding patients: therapeutic strategies** – *G Saglio*
- 11.50 **Updated ELN recommendations for the management of CML** – *F Pane*
- 12.10 **Q&A session** – *Panel*
- 12.25 **Clinical cases 5 & 6** – *F Pane and A Hochhaus*
- 12.45 **Closing address: EUTOS for CML** – *R Hehlmann*
- 13.00 **MEETING CLOSE**

EUTOS for CML



*European Treatment and Outcome Study*